

Puma Biotechnology

Earnings Call

Commercial Update




August 8, 2019

nerlynx[®]
(neratinib) tablets

Forward-Looking Safe Harbor Statement


This presentation contains forward-looking statements, including statements regarding the timing of expected launch and expected regulatory approvals for NERLYNX®. All statements other than historical facts are forward-looking statements and are based on the current expectations, forecasts and assumptions of Puma Biotechnology, Inc. (“Puma”). Forward-looking statements involve risks and uncertainties that could cause Puma’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These risk and uncertainties are identified in Puma’s Annual Report on Form 10-K for the year ended December 31, 2018 and any subsequent documents Puma files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and you should not rely on these forward-looking statements as representing Puma’s views as of any date subsequent to the date of this presentation. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Puma's Pharmacy and Distributor Network




\$53.8 Million Net Sales in Q2 - 2019

18% increase over prior quarter




Bottles Sold By Quarter



• *SP = Specialty Pharmacy Network, SD = Specialty Distributor Network*




Time to First Dispense in Specialty Pharmacy Network



74% of patients receive their first dispense within 15 days of a network SP receiving the RX

75% of Targeted Prescribers Reached



- *Reach defined as physician detailed.*
- *Numbers reported for historical quarters may be slightly different from previous statements due to data updates*

Rest of World Partnerships – Timelines

Region	Partner	Expected Regulatory Approval
Australia / SE Asia	 Specialised Therapeutics	<ul style="list-style-type: none"> • March 2019 – Approved in Australia
Israel	 MEDISON <small>Delivering Innovative Healthcare</small>	<ul style="list-style-type: none"> • Q4 2019
Canada	 Knigh t	<ul style="list-style-type: none"> • July 2019 – Approved
Greater China	 CANbridge 北 海 康 成	<ul style="list-style-type: none"> • Q4 2019 – Hong Kong • 1H 2020 – China • 1H 2020 – Taiwan
Latin America South America	 PINT PHARMA	<ul style="list-style-type: none"> • Q3 2019 – Argentina • 1H 2020 – Chile, Peru • 2H 2020 – Mexico • 2H 2020 – Colombia, Brazil, Ecuador
Europe	 Pierre Fabre	Launch Timelines <ul style="list-style-type: none"> • Q4 2019 – Germany • Q4 2019 – United Kingdom • Q4 2019 – Austria • 2020-2022– Rest of Europe

Puma Biotechnology

Earnings Call

Commercial Update



August 8, 2019

nerlynx[®]
(neratinib) tablets